Specific inhibitors of GALNT enzymes are lacking, but an isozyme-selective inhibitor targeting GALNT3 was recently developed and shown to block the invasion of breast cancer cells with no toxic effects [53], thus paving the way for the discovery of small molecule modulators that control the activity of specific GALNTs. Here, GALNT3 is linked to breast cancer.